2023-03-17 09:43:17 ET
- Pear Therapeutics ( NASDAQ: PEAR ) is exploring strategic alternatives, which among things may include a sale of the company.
- The company has engaged MTS Health Partners as its exclusive financial advisor to assist in evaluating potential alternatives.
- Pear is exploring the potential for an acquisition, company sale, merger, sale of assets, licensing or other transactions, and/or seeking financing.
- The company added that there can be no assurance that the process will lead to pursuing a transaction.
- However, if the company is unable to complete a transaction, it may be required to seek a reorganization, liquidation or other restructuring, Pear noted .
- PEAR -4.28% to $0.57 premarket March 17
For further details see:
Pear Therapeutics stock dips amid plans to explore alternatives, including sale